Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 4

www.gene.com

Discover the latest news about our company, our products, our policies, and our people.

  • Press release announces that polatuzumab with R-CHP vs. RCHOP in front line DLBCL met its primary endpoint by demonstrating significantly improved and clinically meaningful progression-free survival. There is limited information in the press release, but if a true significant improvement would be the first combo to beat RCHOP in >20 years.